The global C-reactive protein testing market size was estimated to be US$ 3.2 Billion in 2022 and is expected to reach US$ 4.25 Billion by 2032 at a CAGR of 2.9%.
Prevalence of cardiovascular diseases, demand for sophisticated diagnostic procedures, and increasing investment in clinical diagnostic are the key factors fueling the growth of C-reactive protein testing market. C-proteins are present in blood to bind to the lysophosphatidylcholine on the surface of dying or dead cells. Rise in blood C-protein level leads to inflammation and acts as an indication of infection or cardiovascular disorders.
The C-reactive protein test is conducted during admission to the hospital or clinics for the treatment of infectious disease or cardiovascular disorders and helps in streamlining the required treatments. According to 2019 statistics published by American Heart Association, around 350,000 incidences of out of hospital cardiac arrest occurs in the United States annually.
As a result of this, healthcare authorities are focusing on establishment of point-of-care testing units to test C-reactive protein levels in blood. The global C-reactive protein market is anticipated to witness significant growth during the forecast period amidst the growth of cardiovascular and cancer incidences around the globe.
North America contributed the largest share to the global C-reactive protein testing market in 2019 and is anticipated to be the dominating geography throughout the forecast period. Prevalence and growth of cardiovascular disorders, prevalence of cancer, and increasing investment on research & development are the major factors fueling the demand and growth of C-reactive protein testing market in North America.
Asia Pacific is anticipated to be the most lucrative market during the forecast period due to increasing number of patients affected with cancer, cardiovascular, and inflammatory bowel disease. Expanding healthcare infrastructure and rising investment in research & development of advanced diagnostic techniques are expected to drive the Asia Pacific C-reactive protein testing market during the forecast period.
The report titled “C-Reactive Protein Testing Market - Global Market Share, Trends, Analysis and Forecasts, 2023-2032” wherein 2021 is the historic period, 2022 is the base year, and 2023 to 2032 is forecast period. Additionally, the study takes into consideration the competitive landscape, wherein the report would provide company overview and market outlook for leading players in the global C-reactive protein testing market. Furthermore, the report would reflect the key developments, global & regional sales network, business strategies, research & development activities, employee strength, and key executive, for all the major players operating in the market. For instance, Danaher Corporation reported revenues of USD 17,911.1 million in 2019 and the product segment analysis of the company indicates that Life Sciences business segment of the company dominated revenue in 2019.
The global C-reactive protein testing market is segmented based on assay type, detection range, application, end user, and geography. Based on assay type, the global C-reactive protein testing market is segmented into immunoturbidimetric assay, enzyme-linked immunosorbent assay (ELISA), chemiluminescence immunoassay, and Others. The enzyme-linked immunosorbent assay (ELISA) is dub-segmented into clinical, and non-clinical C-reactive protein testing. Based on detection range, the global C-reactive protein testing market is segmented into high sensitivity C-reactive protein testing (hs-CRP), conventional CRP, and others. Based on application, the global C-reactive protein testing market is segmented into cardiovascular diseases, cancer, rheumatoid arthritis, inflammatory bowel disease, endometriosis, lupus, and others. Based on end user, the global C-reactive protein testing market is segmented into hospitals, clinics, research laboratories, and others. Based on geography, the global C-reactive protein testing market is segmented into North America, Europe, Asia Pacific, Middle East & Africa, and South America.
The research would provide in-depth analysis of prominent players holding majority share of the global market with a focus on all operating business segment, and would identify the segment of the company focusing on C-reactive protein testing products and technology. Market share of prominent companies in the global C-reactive protein testing market would be included. For instance, Danaher Corporation operates through three business segments namely Life Science, Diagnostics, and Environmental & Applied Solutions. The C-reactive protein testing products and technology is delivered under Life Science business segment of the company with revenue contribution of US$ 7.0 billion in 2019.
The study takes into consideration the key competitive information such as business strategy, product portfolio, key development, SWOT analysis, and research and development focus of all the C-reactive protein testing product and technology companies. Furthermore, the global C-reactive protein testing market study would take into consideration the participants engaged throughout the supply chain and value chain of the market, along with their contribution.
Product portfolio would focus on all the products under the C-reactive protein testing business segment of the company. Similarly, the recent development section would focus on the latest developments of company such as strategic alliances and partnerships, merger and acquisition, new product launched and geographic expansion in the global C-reactive protein testing market.
Major players active in the global C-reactive protein testing market include Abaxis, Inc., Abbott Laboratories, Aidian, BODITECH MED INC., Danaher Corporation, F. Hoffmann-La Roche Ltd., Getein Biotech, Inc., HORIBA, Ltd., Laboratory Corporation of America Holdings, Merck KGaA, Ortho Clinical Diagnostics, Quest Diagnostics Incorporated, Randox Laboratories Ltd., Siemens, and Thermo Fisher Scientific, Inc.
By Assay Type
By Detection Range
By Disease Area
By End Use
By Geography
The C-reactive protein testing market size is expected to reach US$ 4.25 billion by 2032.
The C-reactive protein testing market is expected to grow at a CAGR of 2.9% between 2023 to 2032.
The C-reactive protein testing market size was estimated to be US$ 3.2 billion in 2022.
Prevalence of cardiovascular diseases, demand for sophisticated diagnostic procedures, and increasing investment in clinical diagnostic are the key factors fueling the growth of C-reactive protein testing market.
Major players operating in the global C-Reactive Protein Testing market include Abaxis, Inc., Abbott Laboratories, Aidian, BODITECH MED INC., Danaher Corporation, F. Hoffmann-La Roche Ltd., Getein Biotech, Inc., HORIBA, Ltd., Laboratory Corporation of America Holdings, Merck KGaA, Ortho Clinical Diagnostics, Quest Diagnostics Incorporated, Randox Laboratories Ltd., Siemens, and Thermo Fisher Scientific, Inc..
The sample report for the C-Reactive Protein Testing Market can be obtained on demand from the website. Also, the 24*7 chat support & direct call services are provided to procure the sample report.
Copyright © 2024 Same Page Management Consulting Pvt. Ltd. (insightSLICE) | All Rights Reserved